Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Shanghai Epiprobe Biotechnology Co. Ltd. manages a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 2 pending office actions. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution indicates that the company's technology is being evaluated by different specialized groups, which can provide a broader perspective on how the patent office views their Biotechnology & Pharmaceuticals innovations compared to a portfolio with only 1 distinct examiner.
The busiest examiner for the portfolio is SWITZER, JULIET CAROLINE, who is managing 1 busiest examiner pending office action. Since the total number of pending office actions is 2, this examiner handles the workload associated with that 1 busiest examiner pending office action. The presence of 2 distinct art units suggests that the filings are not concentrated under a single authority. This structure helps mitigate the risk of the portfolio being stalled by the specific requirements of a single examiner. Practitioners can use the feedback from the 2 distinct examiners to refine their overall prosecution strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GIAMMONA, FRANCESCA FILIPPA | 1 | 37.5% | +57.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17250457 | METHYLATION MODIFICATION-BASED TUMOR MARKER STAMP-EP1 | GIAMMONA, FRANCESCA FILIPPA | 30d overdue |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17250457 | METHYLATION MODIFICATION-BASED TUMOR MARKER STAMP-EP1 | GIAMMONA, FRANCESCA FILIPPA | 1681 | §103 | Non-Final OA | 30d overdue | Pending | Sep 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial